From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
 |  | Patients |  |  | ||||||
---|---|---|---|---|---|---|---|---|---|---|
 | All | CK-19mRNA + | CK-19mRNA - |  | ||||||
Characteristic | Number | % | Number | % | Number | % | P | |||
Patients enrolled | 444 | Â | 100 | 181 | Â | 40.8 | 263 | Â | 59.2 | Â |
Age, years | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Median |  | 54 |  |  | 54 |  |  | 55 |  |  |
   Range |  | 26 to 78 |  |  | 26 to 74 |  |  | 30 to 78 |  | 0.752 |
Menopausal status | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.075 |
   Premenopausal | 191 |  | 43 | 87 |  | 45.5 | 104 |  | 54.5 |  |
   Postmenopausal | 253 |  | 57 | 94 |  | 37.2 | 159 |  | 62.8 |  |
Tumor size | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.648 |
   T1 | 157 |  | 35.4 | 61 |  | 38.9 | 96 |  | 61.1 |  |
   T2 | 251 |  | 56.5 | 103 |  | 41 | 148 |  | 59 |  |
   T3 | 36 |  | 8.1 | 17 |  | 47.2 | 19 |  | 52.8 |  |
Histology grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.316 |
   I/II | 204 |  | 46 | 87 |  | 42.6 | 117 |  | 57.4 |  |
   III | 191 |  | 43 | 72 |  | 37.7 | 119 |  | 62.3 |  |
   Unknown | 49 |  | 11 | 22 |  |  | 27 |  |  |  |
Infiltrated axillary lymph nodes | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.538 |
   0 | 163 |  | 36.7 | 61 |  | 37.4 | 102 |  | 62.6 |  |
   1 to 3 | 122 |  | 27.5 | 53 |  | 43.5 | 69 |  | 56.5 |  |
   ≥4 | 159 |  | 35.8 | 67 |  | 42.1 | 92 |  | 57.9 |  |
ER | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.779 |
   Negative | 175 |  | 39.4 | 71 |  | 40.6 | 104 |  | 59.4 |  |
   Positive | 260 |  | 58.6 | 109 |  | 41.9 | 151 |  | 58.1 |  |
   Unknown | 9 |  | 2 | 1 |  |  | 8 |  |  |  |
PR | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.126 |
   Negative | 234 |  | 52.7 | 89 |  | 38 | 145 |  | 62 |  |
   Positive | 201 |  | 45.3 | 91 |  | 45.3 | 110 |  | 54.7 |  |
   Unknown | 9 |  | 2 | 1 |  |  | 8 |  |  |  |
HER2 | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.897 |
   0, 1+ | 290 |  | 65.3 | 122 |  | 42.1 | 168 |  | 57.9 |  |
   2+ | 53 |  | 11.9 | 21 |  | 39.6 | 32 |  | 60.4 |  |
   3+ by IHC | 88 |  | 19.8 | 35 |  | 39.8 | 53 |  | 60.2 |  |
   Unknown | 13 |  | 3 | 3 |  |  | 10 |  |  |  |
Adjuvant chemotherapy | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.425 |
   CMF | 43 |  | 9.7 | 14 |  | 32.6 | 29 |  | 67.4 |  |
   FEC | 209 |  | 47.1 | 84 |  | 40.2 | 125 |  | 59.8 |  |
   EC-T | 192 |  | 43.2 | 83 |  | 43.2 | 109 |  | 56.8 |  |
Surgery | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.478 |
   L | 310 |  | 69.8 | 123 |  | 39.7 | 187 |  | 60.3 |  |
   M | 134 |  | 30.2 | 58 |  | 43.3 | 76 |  | 56.7 |  |
Radiotherapy | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.799 |
   No | 81 |  | 18.2 | 32 |  | 39.5 | 49 |  | 60.5 |  |
   Yes | 363 |  | 81.8 | 149 |  | 41 | 214 |  | 59 |  |